![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 21, 18670-18676, May 24, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 4, 2002, and in revised form, March 6, 2002
12(R)-Hydroxy-5,8,14-eicosatrienoic
acid (HETrE) is a potent inflammatory and angiogenic eicosanoid in
ocular and dermal tissues. Previous studies suggested that
12(R)-HETrE activates microvessel endothelial cells via a
high affinity binding site; however, the cellular mechanisms underlying
12(R)-HETrE angiogenic activity are unexplored. Because the
synthesis of 12(R)-HETrE is induced in response to hypoxic
injury, we examined its interactions with vascular endothelial growth
factor (VEGF) in rabbit limbal microvessel endothelial cells. Addition
of 12(R)-HETrE (0.1 nM) to the cells increased
VEGF mRNA levels with maximum 5-fold increase at 45 min. The
increase in VEGF mRNA was followed by an increase in immunoreactive
VEGF protein. 12(R)-HETrE (0.1 nM) rapidly
activated the extracellular signal-regulated kinases (ERKs) ERK1 and
ERK2. Moreover, preincubation of cells with PD98059, a selective
inhibitor of MEK-1, inhibited 12(R)-HETrE-induced VEGF
mRNA. Addition of VEGF antibody to cells grown in Matrigel-coated
culture plates inhibited 12(R)-HETrE-induced capillary
tube-like formation, suggesting that VEGF mediates, at least in part,
the angiogenic response to 12(R)-HETrE. The results
indicate that in microvessel endothelial cells, 12(R)-HETrE
induces VEGF expression via activation of ERK1/2 and that VEGF
mediates, at least in part, the angiogenic activity of
12(R)-HETrE. Given the fact that both VEGF and
12(R)-HETrE are produced in the cornea after hypoxic
injury, their interaction may be an important determinant in the
development of neovascularized tissues.
A wide variety of disorders of the cornea evoke a vasculogenic
response; a considerable amount of information has accumulated about
the circumstances under which newly formed blood vessels sprout and
extend centripetally into the cornea. Thus, the cornea has become a
standard model for the study of angiogenesis. Vascularized corneas are
clinically significant because they diminish visual acuity.
Diverse mediators have been implicated in the process of corneal
angiogenesis including prostaglandins, vasoactive amines, epithelial
angiogenic factors, and components of leukocytic extracts (1). We have
identified a corneal epithelial-derived eicosanoid, 12(R)-hydroxy-5,8,14-eicosatrienoic acid
(HETrE)1 and characterized it
as a novel inflammatory and angiogenic mediator; it is produced by the
corneal epithelium in response to injury, displays potent inflammatory
properties, is a mitogen for microvascular endothelial cells, and is
angiogenic in vitro and in vivo. Moreover, after
hypoxic and chemical injury to the corneal epithelium,
12(R)-HETrE is produced at a rate of 60-100 pmol/h/mg,
which is sufficient to elicit its effect on the adjacent capillary
endothelial cells of the limbal vessels. The increased synthesis of
this eicosanoid after injury is observed within 1 day of the injury,
sustained for several days (up to 7-9 days), and correlates well
(r = 0.963; p < 0.04) with the degree
of inflammation (2-4). In vitro, 12(R)-HETrE synthesis is markedly increased in response to hypoxia (5). Moreover,
12(R)-HETrE is readily released into the incubation medium
of cultured injured rabbit corneas, and its levels were found to be
dramatically increased in tears from inflamed human eyes (6, 7)
suggesting a paracrine role for 12(R)-HETrE. We therefore
postulate that 12(R)-HETrE is a tissue-derived angiogenic factor whose synthesis is induced in response to injury, acting in a
paracrine manner on microvessels to activate endothelial cells via a
specific receptor/binding site resulting in an angiogenic phenotype.
It should be noted that the synthesis and activity of
12(R)-HETrE extend beyond the ocular surface; its synthesis
has been documented in rat epidermal microsomes (8, 9) and porcine neutrophils (10). 12(R)-HETrE is a potent chemoattractant
for human neutrophils (11), and in guinea pig skin, it enhances delayed-type hypersensitivity inflammatory reactions at doses as low as
1 fmol (12).
The cellular mechanisms underlying the angiogenic activity of
12(R)-HETrE are still unclear. We have identified several
events involved in the signal transduction of endothelial cells
stimulated by 12(R)-HETrE including the demonstration of a
putative receptor in limbal microvessel endothelial cells (13), a
protein kinase C-dependent nuclear factor Materials--
12(R)-HETrE and 12(S)-HETrE
were synthesized and purified as described previously (16). The
identity and purity of each compound were confirmed by chiral HPLC and
gas chromatography/mass spectrometry. Stock solutions were prepared in
ethanol and stored at Cell Culture--
Primary cultures of rabbit limbal
microvascular endothelial (RLME) cells were obtained via an
in vitro angiogenesis assay as described previously (17).
Cells were grown, and their endothelial identity was examined at random
by measuring factor VIII antigen immunofluorescence. Cells were
cultured in Dulbecco's modified Eagle's medium (Cellgro, Herndon, VA)
supplemented with 10% fetal bovine serum (Cellgro), 1%
antibiotic-antimycotic (Cellgro), and endothelial cell growth
supplements (ECGS; Sigma). Before each experiment, cells were washed
twice in phosphate-buffered saline, pH 7.6, and quiesced in antibiotic-
and growth factor-free Dulbecco's modified Eagle's medium containing
0.5% fetal bovine serum for 24-36 h.
Measurements of VEGF mRNA Expression--
Monolayer-grown
cells were promptly homogenized in Trireagent (Sigma). Cell homogenates
were quick-frozen and stored at Measurements of VEGF Protein Levels--
VEGF protein levels in
the culture medium were measured by enzyme-linked immunosorbent assay
using a Mouse VEGF Quantikine M Immunoassay Kit (R&D Systems,
Minneapolis, MN) according to the manufacturer's instructions.
Quantitation of samples was determined from the least squares
regression analysis of a linear standard curve obtained with
recombinant mouse VEGF as control. Protein concentration was determined
by the Bradford method (Sigma).
Western Blot--
Cells were harvested, resuspended in lysis
buffer (Cell Signaling Technology), and sonicated (4 °C, 5 × 1 min). Cell-free homogenates were prepared by centrifugation at
6000 × g for 5 min. Aliquots of cell-free homogenates
(150 µg) were denatured in Laemmli loading buffer (2 min at
95 °C), resolved on 11% or 14% SDS-polyacrylamide gels, and
transferred onto polyvinylidene difluoride membranes (Bio-Rad).
Membranes were hybridized with the antibodies indicated in the text,
and immunoreactive bands were detected using chemiluminescence
substrates according to the manufacturer's instructions and
visualized after exposure to HyperfilmTM ECL (Amersham
Biosciences). The autoradiographed films were scanned, and densitometry
analysis was performed with Scion Image software using a Kodak gray
color scale as a standard.
ERK Kinase Assay--
Kinase assays were performed using a
p44/p42 (ERK1/2) MAPK kinase assay kit (Cell Signaling Technology)
according to the manufacturer's protocol. Briefly, activated ERK was
precipitated from cell lysates using immobilized phospho-ERK1/2 MAP
kinase (Tyr202/Tyr204) antibodies. The
precipitates were incubated with recombinant Elk-1, a specific ERK
substrate, and ATP. The reaction was terminated by adding boiling
gel-loading buffer. ERK activity was detected by immunoblotting the
products of the kinase reaction with anti-phospho-Elk-specific antibody.
In Vitro Capillary Tube-like Formation--
Assessment of
in vitro capillary tube-like formation utilized growth
factor reduced basement membrane Matrigel matrix (BD Biosciences-Discovery Labware). The Matrigel was thawed overnight at
4 °C and mixed to homogeneity using cooled pipette tips. Aliquots of
Matrigel (250 µl) were distributed as a thin layer on the bottom of
12-well cell culture plates and left for polymerization at 37 °C for
30 min. Quiesced RLME cells were resuspended in Dulbecco's modified
Eagle's medium containing 0.5% fetal bovine serum to give a final
cell concentration of 1 × 105 cells/ml, plated onto
the Matrigel-coated surface, and incubated for 1 h in a 37 °C
humidified incubator. The medium was aspirated to remove nonattached
cells and substituted by fresh medium containing vehicle or the test
compounds. Tube-like structure formation was examined at 8, 16, and
24 h after treatment. Cultures were photographed, and the length
of the tube-like was structures was quantified using Image Pro-Express
Software (Cyber Media).
12(R)-HETrE Induces VEGF Expression--
Incubation of RLME cells
with 12(R)-HETrE at concentration of 0.1 nM
resulted in a rapid induction of VEGF expression. As seen in Fig.
1A, 12(R)-HETrE
increased VEGF mRNA levels in a time-dependent manner.
A 5-fold increase over the control levels was observed 45 min after the
addition of 12(R)-HETrE, and these levels gradually declined
to the control levels by 48 h. Incubation of cells with cycloheximide did not affect 12(R)-HETrE-induced VEGF
mRNA, suggesting that the induction does not require de
novo protein synthesis. On the other hand, addition of actinomycin
D abolished 12(R)-HETrE-induced VEGF expression, indicating
that this effect requires de novo RNA synthesis (Fig.
1B). To determine whether the effect of
12(R)-HETrE is due in part to an increase in the stability
of VEGF mRNA, we performed a standard mRNA decay assay using
actinomycin D. As seen in Fig. 1C, the half-life of VEGF
mRNA was 9.15 ± 1.26 h in the absence of
12(R)-HETrE and 13.46 ± 1.46 h in the presence of
12(R)-HETrE (n = 3; p = 0.018), suggesting that both transcriptional activation and mRNA
stabilization accounted for the increase in VEGF mRNA induced by
12(R)-HETrE. 12(R)-HETrE increased VEGF mRNA in a concentration-dependent manner, with 0.1 nM 12(R)-HETrE having the maximal effect (Fig.
2). Moreover, this effect was
stereospecific because the S enantiomer did not significantly affect
VEGF expression at concentrations of up to 10 nM (Fig. 2);
VEGF mRNA levels were 115 ± 26%, 65 ± 31%, and
99 ± 22% of control levels at 0.1, 1, and 10 nM
12(S)-HETrE (mean + S.E.; n = 3). Northern
blot analysis indicated the presence of two VEGF transcripts with
estimated sizes of 2.4 and 4.2 kb. 12(R)-HETrE induced the
level of expression of both transcripts in a
concentration-dependent manner (Fig. 3).
The increase in VEGF mRNA in response to 12(R)-HETrE was
followed by an increase in its protein levels. As seen in Fig.
4A, VEGF protein levels in the
culture media of cells incubated with 0.1 nM
12(R)-HETrE increased in a time-dependent manner
with a significant increase at 3 h and a 4-fold increase at
24 h after the addition of 12(R)-HETrE. The
12(R)-HETrE-stimulated increase in VEGF protein was also
concentration-dependent (Fig. 4B).
12(R)-HETrE Induces VEGF Expression via a
MAPK-dependent Pathway--
The mechanism by which
12(R)-HETrE induces VEGF expression is unknown. The p44/p42
(ERK1/2) MAP kinase signaling pathway has been implicated in a wide
range of cellular functions including the control of VEGF expression in
endothelial cells (19). We examined whether the
12(R)-HETrE-induced increase in VEGF expression in RLME
cells involves the activation of the ERK1/2 MAP kinases. After the
addition of 0.1 nM 12(R)-HETrE to the cells,
both ERK1 and ERK2 were transiently activated as determined by Western
blot analyses with antibody against the phosphorylated forms of ERK1/2 (Fig. 5). Kinase activation peaked at 5 min and gradually decreased to control levels by 60 min. Additional
in vitro kinase assays demonstrated an increase in
phosphorylation of Elk, the MAPK-specific substrate, which paralleled
the increase in ERK1/2 activity (Fig. 6,
A and B). The increase in kinase activity was
inhibited by the MEK inhibitor PD98059 (Fig. 6C), suggesting
that MEK, the immediate upstream dual specificity kinase to ERK, is
involved in 12(R)-HETrE-stimulated ERK1/2 activity. The
observation that activation of ERK1/2 is involved in
12(R)-HETrE-induced VEGF expression is further documented in
Fig. 7. Preincubation of cells with
PD98059 (5 µM) before the addition of
12(R)-HETrE (0.1 nM) inhibited the increase
in VEGF mRNA by 50%.
Inhibition of VEGF Attenuates Angiogenic Activity of
12(R)-HETrE--
We used the in vitro capillary tube-like
formation in cells embedded in a coating of basement membrane Matrigel
to assess the angiogenic activity of 12(R)-HETrE and
examined whether it involves VEGF production. As seen in Fig.
8A, 12(R)-HETrE at
a concentration as low as 1 pM stimulated capillary
tube-like formation within 24 h. This effect was
concentration-dependent, with the maximal stimulation achieved
at 0.1 nM (Fig. 8A). Moreover, this effect was
stereospecific because the S enantiomer,
12(S)-HETrE, at a concentration of up to 10 nM
had little effect on tube-like capillary formation (Fig.
8B). Importantly, the addition of VEGF antibodies to the
incubation medium greatly attenuated 12(R)-HETrE-stimulated capillary tube-like formation (Fig. 7C), indicating that the
12(R)-HETrE stimulatory effect is mediated, at least in
part, by VEGF.
12(R)-HETrE possesses biological activities in
vitro and in vivo that are characteristic of a
pro-inflammatory factor: vasodilation increased capillary permeability,
neutrophil chemotaxis, and angiogenesis. The most fascinating aspect of
these responses is that they are elicited by picogram to nanogram
quantities, which readily can be found in injured tissues. The
synthesis of 12(R)-HETrE in the corneal epithelium has been
extensively studied. It is formed via a cytochrome
P450-dependent pathway from either arachidonic acid or
12-hydroxyeicosatetraenoic acid (20). The production of this eicosanoid
by the corneal epithelium in response to hypoxic or chemical injury
correlated with the inflammatory response, which included
neovascularization of the cornea. Furthermore, inhibition of its
formation by depleting cytochrome P450 in the corneal epithelium
attenuated the inflammatory response after hypoxic injury (3).
Additional studies identified CYP4B1 as the hypoxia-induced cytochrome
P450 enzyme involved in the synthesis of 12(R)-HETrE (21).
Hypoxic injury to the corneal surface increases the expression of both
CYP4B1 and VEGF (22), suggesting a potential interaction between these
pathways in the implementation of the inflammatory and angiogenic
response after such an injury.
The primary target cells of 12(R)-HETrE are the microvessel
endothelial cells. Binding studies indicated the presence of a high
affinity, low capacity receptor/binding site in these cells. Additional
studies identified several events that occurred in microvessel
endothelial cells in response to 12(R)-HETrE including a
protein kinase C-dependent nuclear factor The current study describes a novel mechanism for
12(R)-HETrE-induced angiogenesis. The results indicate that
it is a potent inducer of VEGF expression in microvessel endothelial
cells and that its angiogenic activity, measured as the ability to form capillary tube-like structures in culture, is mediated in part by VEGF.
The results also suggest that 12(R)-HETrE induces VEGF expression via activation of the ERK1/2 MAPK signaling pathway, a
pathway that has long been implicated in the regulation of VEGF expression in endothelial cells, especially under hypoxic conditions (23).
12(R)-HETrE is not the only angiogenic eicosanoid; however,
as documented previously and seen in this study, it is one of the most
potent. It stimulates capillary tube-like formation at concentrations
as low as 1 pM. Its maximal stimulatory effect in inducing
VEGF expression and eliciting an angiogenic response is obtained at 0.1 nM, a concentration that is approximately two times the
estimated binding affinity of 12(R)-HETrE in these cells (13). Among other eicosanoids, prostaglandins have long been thought to
promote angiogenesis, although they do not directly stimulate
endothelial cell growth (24, 25). Their angiogenic effect is believed
to be mediated by paracrine actions on angiogenic factors such as basic
fibroblast growth factor and VEGF (26, 27). Other cyclooxygenase
metabolites have been implicated in the process of angiogenesis. For
example a thromboxane A2 agonist has been shown to increase endothelial
cell proliferation and migration (28). Studies by Honn and colleagues
(29) demonstrated that endothelial 12-lipoxygenase produces
12(S)-HETE, which in turn is capable of stimulating cell
proliferation, migration, and capillary tube-like formation when added
at nanomolar to micromolar concentrations. These investigators
suggested that endogenous 12-lipoxygenase is involved in the
endothelial cell angiogenic response by showing that enzymatic
inhibitors reduced growth factor-stimulated cell proliferation,
migration, and capillary tube-like formation. The cytochrome
P450-derived epoxyeicosatrienoic acids have been shown to act as
mitogens in various cell types including vascular endothelial cells
(30). A potential role for epoxyeicosatrienoic acids in the regulation
of angiogenesis has been implicated from studies showing that
astrocytes are capable of inducing capillary angiogenesis that appears
to be mediated in part by epoxyeicosatrienoic acids (31).
Our study shows that 12(R)-HETrE increased VEGF mRNA by
a mechanism that includes both activation of transcription and
stabilization of mRNA as evidenced by sensitivity to actinomycin D
and an increased half-life of VEGF mRNA. The increase in VEGF
mRNA was very rapid; a significant increase was seen 15 min after
the addition of 12(R)-HETrE. Other eicosanoids such as
prostaglandin E2 have been shown to increase VEGF
expression primarily by transcriptional activation and mostly within
hours of cell exposure to these prostanoids (26, 27, 32-34). Our study
also shows that 12(R)-HETrE increases VEGF mRNA via
activation of a MAPK signaling pathway, namely, ERK1/2.
12(R)-HETrE at concentration of 0.1 nM increased
ERK1/2 phosphorylation within 5 min, and this activation resulted in increased kinase activity. Moreover, the ability of PD98059 to inhibit 12(R)-HETrE-induced VEGF mRNA indicates that a
MEK-1-dependent activation of ERK1/2 is part of the
cellular mechanism that underlies the effect of 12(R)-HETrE
on VEGF gene expression. Numerous studies have documented a key role
for the ERK1/2 MAP kinase pathway in angiogenesis; these studies
include evidence that ERK1/2 MAP kinase activity is critical for the
control of endothelial cell proliferation and growth arrest and that
these kinases promote VEGF expression via transcriptional activation
(Ref. 19 and the references therein). More importantly, ERK1/2 MAP
kinases have been shown to directly phosphorylate (HIF)-1 The relevance of 12(R)-HETrE is further enhanced by the fact
that its formation is also seen in other tissues and that its topical
application elicits biological activities typical of inflammatory factors. The presence of an eicosanoid with an HPLC retention time
similar to that of 12-HETrE was documented in human psoriatic lesions
(35). Rat epidermal microsomes have been shown to produce 12-HETrE
enantiomers by an NADPH-dependent mechanism (8, 9). Production of 12-HETrE from 12-hydroxyeicosatetraenoic acid was also
documented in porcine neutrophils (10). In guinea pig skin, 12(R)-HETrE increases delayed-type hypersensitivity
inflammatory reactions at doses as low as 1 fmol (12).
12(R)-HETrE is present in human tears, and its levels are
many fold higher in tears from inflamed eyes (7). This latter finding
suggests that this eicosanoid is relevant to human pathophysiology. It
should be noted that 12(R)-HETrE is a potent
chemoattractant, whereas VEGF is not (11). Thus, 12(R)-HETrE
could be critical to the activity of VEGF not only by inducing its
expression in the injured tissue and its vascular surroundings but also
by providing the chemoattractant activity for polymorphonuclear
cells, a major source of VEGF. This relationship could also be
significant in the generation of chronic inflammation, a major clinical
problem, because neovascularization is necessary to maintain chronic
inflammation (36).
*
This work was supported by Grants EY06513 and GM31278 from
the National Institutes of Health and by the Robert A. Welch
Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, March 18, 2002, DOI 10.1074/jbc.M201143200
2
P. A. Mieyal and M. Laniado-Schwartzman,
unpublished data.
The abbreviations used are:
HETrE, hydroxy-5,8,14-eicosatrienoic acid;
VEGF, vascular endothelial growth
factor;
RLME, rabbit limbal microvessel endothelial;
MAP, mitogen-activated protein;
MAPK, MAP kinase;
ERK, extracellular
signal-regulated kinase;
MEK, MAPK/ERK kinase;
HPLC, high pressure
liquid chromatography.
Eicosanoid Regulation of Vascular Endothelial Growth
Factor Expression and Angiogenesis in Microvessel Endothelial
Cells*
,
,
,
Department of Pharmacology, New York Medical
College, Valhalla, New York 10595 and Departments of
§ Biochemistry and ¶ Pharmacology, University of Texas
Southwestern Medical Center, Dallas, Texas 75235
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B activation
(14), and increased c-fos, c-jun and
c-myc oncogene expression (15). The mechanism by which
12(R)-HETrE promotes the angiogenic response of the
endothelial cells may involve the induction of peptide angiogenic
factors, primarily VEGF. The current study examines whether VEGF is a
component of the angiogenic activity of 12(R)-HETrE and
characterizes mechanisms underlying the effect of
12(R)-HETrE on VEGF expression.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 °C. The ethanol stocks were dried under
nitrogen, and dilutions for each experiment were prepared in 0.01%
Me2SO. Actinomycin D, cycloheximide, and PD98059 were
purchased from Sigma. Anti-ERK1/2 and anti-phospho-specific ERK
antibodies were purchased from Cell Signaling Technology (Beverly, MA).
80 °C until use. Total RNA was
extracted (18) and denatured in the presence of a 1× RNA sample
loading buffer (Sigma). For Northern analysis, denatured RNA was
electrophoresed on 1.2% agarose formaldehyde gels and transferred to
Hybond-N+ membranes (Amersham Biosciences). For slot blot
hybridization, denatured RNA was blotted to Hybond-N+ membranes using a
slot blot filtration manifold (Schleicher & Schuell). Membranes were
cross-linked (1200 mkJ/cm2), dried at 80 °C for 2 h, and incubated overnight in hybridization buffer containing the
32P-end-labeled mouse VEGF cDNA probe at 65 °C.
Hybridization signals were visualized by radiography and quantitated
using Scion Image software (National Institutes of Health, Bethesda,
MD) and a Kodak gray color scale as a standard. Each membrane was
stripped and rehybridized with a 32P-end-labeled
-tubulin cDNA probe. VEGF mRNA levels were normalized to
-tubulin to correct loading variation.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (21K):
[in a new window]
Fig. 1.
12(R)-HETrE induction of
VEGF mRNA in RLME cells. A,
time-dependent induction of VEGF mRNA.
Subconfluent RLME cells (50-70%) were quiesced for 36 h
in serum-deprived medium and further exposed to 0.1 nM
12(R)-HETrE. At the indicated time points, cells were lysed,
and total RNA was isolated and analyzed by slot blot hybridization with
a mouse cDNA probe as described under "Experimental
Procedures." Membranes were stripped and reprobed with
-tubulin as
a housekeeping gene. VEGF mRNA levels were normalized to
-tubulin to correct loading variations. Results of densitometry
analysis represent fold increases from control of the ratio of VEGF
mRNA to
-tubulin mRNA in nontreated cells (t = 0 min). The results are the mean ± S.E.; n = 3;
*, p < 0.05 from the control. B, effect
of actinomycin D (Act D) and cycloheximide (CHX)
on 12(R)-HETrE-induced VEGF mRNA. Quiesced subconfluent
RLME cells were treated with 12(R)-HETrE (0.1 nM) with and without actinomycin D (10 µM) or
cycloheximide (10 µM) for 45 min. Concentrations of both
actinomycin D and cycloheximide were 10 µM. VEGF mRNA
was measured as described above. The blot is representative of three
separate experiments. C, effect of 12(R)-HETrE on
VEGF mRNA half-life. Quiesced subconfluent RLME cells were
incubated with either 12(R)-HETrE (0.1 nM) (
) or vehicle
(
) for 45 min before the addition of actinomycin D (10 µM). Total RNA was extracted from cells at the indicated
times after the addition of actinomycin D. VEGF mRNA level was
analyzed by slot blot hybridization as described above. VEGF mRNA
levels were normalized to
-tubulin, and the decay rates were plotted
as a percentage of the 0 h value against time. Half-life of VEGF
mRNA was 13.46 ± 1.46 h in the absence of
12(R)-HETrE and 9.15 ± 1.26 h in the presence of
12(R)-HETrE (mean ± S.E.; n = 3;
p = 0.018 between groups).

View larger version (45K):
[in a new window]
Fig. 2.
Concentration-dependent induction
of VEGF mRNA synthesis by 12(R)-HETrE in RLME
cells. Subconfluent (50-70%) RLME cells were quiesced for
36 h in a serum-deprived medium and further incubated with
12(R)-HETrE (0.01-10 nM) or
12(S)-HETrE (10 nM) for 45 min. VEGF mRNA
levels were measured by slot blot hybridization and densitometry
analysis normalized to
-tubulin levels as described under
"Experimental Procedures." Results are the mean ± S.E.;
n = 4; *, p < 0.05 from the vehicle
control.

View larger version (61K):
[in a new window]
Fig. 3.
VEGF Northern blot. Subconfluent
(50-70%) RLME cells were quiesced for 36 h in serum-deprived
medium and further incubated with 12(R)-HETrE
(0.01-10 nM) for 45 min. VEGF mRNA levels were
measured by Northern blot hybridization using the mouse VEGF cDNA
probe as described under "Experimental Procedures."

View larger version (15K):
[in a new window]
Fig. 4.
12(R)-HETrE stimulation of
VEGF protein in culture medium of RLME cells. A,
time-dependent. Quiesced subconfluent RLME cells were
treated with 12(R)-HETrE for 1-48 h. At the indicated time
points, aliquots of cell culture medium (500 µl) were collected and
analyzed for VEGF protein by enzyme-linked immunosorbent assay as
described under "Experimental Procedures." Results are the
mean ± S.E.; n = 5; *, p < 0.05 from the vehicle control. B,
concentration-dependent. Quiesced subconfluent RLME cells
were treated with various concentrations of
12(R)-HETrE (0.01-10 nM) for 24 h.
Aliquots of cell culture medium (500 µl) were collected and analyzed
for VEGF protein by enzyme-linked immunosorbent assay as described
under "Experimental Procedures." Results are the mean ± S.E.;
n = 5; *, p < 0.05 from the vehicle
control.

View larger version (28K):
[in a new window]
Fig. 5.
12(R)-HETrE activation of
ERK1/2 in RLME cells. Quiesced subconfluent RLME cells were
treated with 12(R)-HETrE (0.1 nM) for the
indicated times. Western blot analyses of whole cell lysates were
performed with antibodies specific to the phosphorylated and
unphosphorylated forms of ERK1/2 as described under "Experimental
Procedures." Blots were stripped and reprobed with nonphosphorylated
specific ERK antibody for loading control. A, a
representative Western blot of whole cell lysates for activated
(phosphorylated) ERK1/2 and nonphosphorylated ERK1/2. B,
results of densitometry analysis of the ratio of phosphorylated to
nonphosphorylated ERK1/2 are given as percentage of control
(t = 0) and are the mean ± S.E.,
n = 3; *, p < 0.05 from
control.

View larger version (29K):
[in a new window]
Fig. 6.
12(R)-HETrE stimulation of
ERK1/2 activity in RLME cells. Quiesced subconfluent RLME cells
were incubated with 12(R)-HETrE (0.1 nM) for
5-60 min. ERK activity was determined using the specific substrate Elk
as described under "Experimental Procedures." A and
B, time-dependent stimulation of ERK1/2
activity. Results are given as a percentage of control
(t = 0) and are the mean ± S.E.;
n = 3; *, p < 0.05 from control.
C, 12(R)-HETrE-activated ERK1/2 is inhibited by
the MEK-specific inhibitor PD98059. Quiesced subconfluent RLME cells
were preincubated with PD98059 (5 µM) for 15 min before
the addition of 12(R)-HETrE (0.1 nM). ERK
activity was determined using the specific substrate Elk as described
under "Experimental Procedures." Western blot of whole cell lysates
with anti-phospho-Elk antibody is representative of three blots from
three separate experiments.

View larger version (23K):
[in a new window]
Fig. 7.
Effect of MEK inhibition on
12(R)-HETrE-induced VEGF mRNA. Quiesced
subconfluent RLME cells (50-70%) were incubated with
12(R)-HETrE with either 12(R)-HETrE (0.1 nM) or 12(R)-HETrE (0.1 nM) plus
PD98059 (5 µM) for 1 h. VEGF mRNA levels were
measured by slot blot hybridization with the mouse VEGF cDNA
and determined by densitometry analysis using
-tubulin mRNA for
normalization. Results are given as a percentage of control untreated
cells and are the mean ± S.E.; n = 3; *,
p < 0.05 from control; #, p < 0.05 from 12(R)-HETrE-treated cells.

View larger version (49K):
[in a new window]
Fig. 8.
12(R)-HETrE
stimulation of capillary-like network formation in RLME cells.
A, quiesced subconfluent RLME cells plated in a 12-well
culture dish (1 × 105 cells/well) precoated with
Matrigel were incubated with various concentrations of
12(R)-HETrE (1 pM to 10 nM) for 16 or 24 h. Photographs were taken at ×10 magnification. Maximal
response was obtained at 24 h after the addition of
12(R)-HETrE. Capillary length was measured by image analysis
using Image Pro software as described under "Experimental
Procedures." Results of capillary length after 24 h as a
function of 12(R)-HETrE concentrations are the mean ± S.E.; n = 3; *, p < 0.05 from
control untreated cells. B, stereospecificity of
12(R)-HETrE effect on capillary-like network formation.
Quiesced subconfluent RLME cells plated in a 12-well culture dish
precoated with Matrigel were incubated with 12(R)-HETrE (0.1 nM) or 12(S)-HETrE (10 nM) for
24 h. Photographs were taken at ×10 magnification. Capillary
length was measured by image analysis using Image Pro software as
described under "Experimental Procedures." Results of capillary
length are the mean ± S.E.; n = 3; *,
p < 0.05 from control untreated cells. C,
inhibition of 12(R)-HETrE stimulated capillary- like tube
formation by anti-VEGF-specific antibody. Quiesced subconfluent RLME
cells were plated in 12-well culture dishes precoated with
Matrigel and incubated with 12(R)-HETrE (0.1 nM)
or 12(R)-HETrE (0.1 nM) plus anti-VEGF-specific
antibodies (1:1000) for 24 h. Photographs were taken at ×10
magnification. Capillary length was measured by image analysis using
Image Pro software as described under "Experimental Procedures."
Results of capillary length are the mean ± S.E.;
n = 3; *, p < 0.05 from
control.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B activation
(14), increased c-fos, c-jun, and
c-myc oncogene expression (15), and a Phospholipase
C-inositol 1,4,5-trisphosphate-mediated increase in
intracellular Ca2+ concentration
([Ca2+]i).2
Each of these events may contribute to the angiogenic activity of
12(R)-HETrE because the transformation of endothelial
cells from the resting state to an angiogenic phenotype is a complex process requiring multiple steps to occur before new capillaries are
formed. We postulated that 12(R)-HETrE released by the
injured tissue acts on neighboring microvessel endothelial cells and
triggers key steps to initiate the angiogenic transformation. With
regard to these key steps in angiogenic transformation, the current
study links 12(R)-HETrE to the induction of VEGF, one of the
most potent peptide angiogenic factors of endothelial cell origin.
, a
key step in the activation of HIF-1 transcription factor (23). The
latter is essential for VEGF increased gene expression in response to
hypoxia. The fact that 12(R)-HETrE is produced in response
to hypoxia raises the possibility that this eicosanoid serves as
amplifier of the hypoxic induction of VEGF through activation of the
ERK1/2.
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of
Pharmacology, New York Medical College, Basic Science Bldg. 530, Valhalla, NY 10595. Tel.: 914-594-4153; Fax: 914-594-4303; E-mail:
michal_schwartzman@nymc.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Klintworth, G. K.
(1990)
Corneal Angiogenesis: A Comprehensive Critical Review
, Springer-Verlag, New York
2.
Conners, M. S.,
Stoltz, R. A.,
Webb, S. C.,
Rosenberg, J.,
Dunn, M. W.,
Abraham, N. G.,
and Schwartzman, M. L.
(1995)
Invest. Ophthalmol. Vis. Sci.
36,
828-840[Abstract]
3.
Conners, M. S.,
Stoltz, R. A.,
Dunn, M. W.,
Levere, R. D.,
Abraham, N. G.,
and Schwartzman, M. L.
(1995)
Invest. Ophthalmol. Vis. Sci.
36,
841-850 4.
Conners, M. S.,
Urbano, F.,
Vafeas, C.,
Stoltz, R. A.,
Dunn, M. W.,
and Laniado Schwartzman, M.
(1997)
Invest. Ophthalmol. Vis. Sci.
38,
1963-1971 5.
Vafeas, C.,
Mieyal, P. A.,
Urbano, F.,
Falck, J. R.,
Chauhan, K.,
Berman, M.,
and Laniado Schwartzman, M.
(1998)
J. Pharmacol. Exp. Ther.
287,
903-910 6.
Mieyal, P. A.,
Bonazzi, A.,
Jiang, H.,
Dunn, M. W.,
and Laniado-Schwartzman, M.
(2000)
Invest. Ophthalmol. Vis. Sci.
41,
2170-2176 7.
Mieyal, P. A.,
Dunn, M. W.,
and Schwartzman, M. L.
(2001)
Invest. Ophthalmol. Vis. Sci.
42,
328-332 8.
Holtzman, M. J.,
Turk, J.,
and Pentland, A.
(1989)
J. Clin. Invest.
84,
1446-1453[Medline]
[Order article via Infotrieve]
9.
Van Wauwe, J.,
Coene, M.-C.,
Van Nyen, G.,
Cools, W.,
Goossen, J.,
LeJeune, L.,
Lauwers, W.,
and Janssen, P. A. J.
(1991)
Eicosanoids
4,
155-163[Medline]
[Order article via Infotrieve]
10.
Wainwright, S.,
Falck, J. R.,
Yadagiri, P.,
and Powell, W. S.
(1990)
Biochemistry
29,
10126-10135[CrossRef][Medline]
[Order article via Infotrieve]
11.
Masferrer, J. L.,
Rimarachin, J. A.,
Gerritsen, M. E.,
Falck, J. R.,
Yadagiri, P.,
Dunn, M. W.,
and Schwartzman, M. L.
(1991)
Exp. Eye Res.
52,
417-424[CrossRef][Medline]
[Order article via Infotrieve]
12.
Conners, M. S.,
Godfrey, H.,
Chauhan, K.,
Falck, J. R.,
and Laniado-Schwartzman, M.
(1994)
J. Invest. Dermatol.
104,
1-5[CrossRef]
13.
Stoltz, R. A.,
and Laniado Schwartzman, M.
(1997)
J. Ocul. Pharmacol. Ther.
13,
191-199[Medline]
[Order article via Infotrieve]
14.
Stoltz, R. A.,
Abraham, N. G.,
and Laniado Schwartzman, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2832-2837 15.
Laniado-Schwartzman, M.,
Lavrovsky, Y.,
Stoltz, R. A.,
Conners, M. S.,
Falck, J. R.,
Chauhan, K.,
and Abraham, N. G.
(1994)
J. Biol. Chem.
269,
24321-24327 16.
Shin, D.-S.,
Yadagiri, P.,
Falck, J. R.,
Masferrer, J. L.,
and Schwartzman, M. L.
(1989)
Tetrahedron Lett.
30,
3923-3926
17.
Stoltz, R. A.,
Conners, M. S.,
Gerritsen, M. E.,
Abraham, N. G.,
and Laniado-Schwartzman, M.
(1996)
Am. J. Pathol.
148,
129-139[Abstract]
18.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
19.
Pages, G.,
Milanini, J.,
Richard, D. E.,
Berra, E.,
Gothie, E.,
Vinals, F.,
and Pouyssegur, J.
(2000)
Ann. N. Y. Acad. Sci.
902,
187-200[CrossRef][Medline]
[Order article via Infotrieve]
20.
Laniado Schwartzman, M.
(1997)
in
Advances in Ocular Toxicology
(Green, K.
, Edelhauser, H. F.
, Hackett, R. B.
, Hull, D. S.
, Potter, D. E.
, and Tripathi, R. C., eds)
, pp. 3-20, Plenum Press, New York
21.
Mastyugin, V.,
Aversa, E.,
Vafeas, C.,
Mieyal, P.,
and Laniado Schwartzman, M.
(1999)
J. Pharmacol. Exp. Ther.
289,
1611-1619 22.
Mastyugin, V.,
Mosaed, S.,
Bonazzi, A.,
Dunn, M. W.,
and Laniado-Schwartzman, M.
(2001)
Curr. Eye Res.
23,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
23.
Berra, E.,
Milanini, J.,
Richard, D. E., Le,
Gall, M.,
Vinals, F.,
Gothie, E.,
Roux, D.,
Pages, G.,
and Pouyssegur, J.
(2000)
Biochem. Pharmacol.
60,
1171-1178[CrossRef][Medline]
[Order article via Infotrieve]
24.
Form, D. M.,
and Auerbach, R.
(1983)
Proc. Soc. Exp. Biol. Med.
172,
214-218[Abstract]
25.
Leahy, K. M.,
Koki, A. T.,
and Masferrer, J. L.
(2000)
Curr. Med. Chem.
7,
1163-1170[Medline]
[Order article via Infotrieve]
26.
Pai, R.,
Szabo, I. L.,
Soreghan, B. A.,
Atay, S.,
Kawanaka, H.,
and Tarnawski, A. S.
(2001)
Biochem. Biophys. Res. Commun.
286,
923-928[CrossRef][Medline]
[Order article via Infotrieve]
27.
Bamba, H.,
Ota, S.,
Kato, A.,
Kawamoto, C.,
and Fujiwara, K.
(2000)
Biochem. Biophys. Res. Commun.
273,
485-491[CrossRef][Medline]
[Order article via Infotrieve]
28.
Nie, D.,
Lamberti, M.,
Zacharek, A., Li, L.,
Szekeres, K.,
Tang, K.,
Chen, Y.,
and Honn, K. V.
(2000)
Biochem. Biophys. Res. Commun.
267,
245-251[CrossRef][Medline]
[Order article via Infotrieve]
29.
Nie, D.,
Tang, K.,
Diglio, C.,
and Honn, K. V.
(2000)
Blood
95,
2304-2311 30.
Fleming, I.,
Fisslthaler, B.,
Michaelis, U. R.,
Kiss, L.,
Popp, R.,
and Busse, R.
(2001)
Pfluegers Archiv.
442,
511-518[CrossRef][Medline]
[Order article via Infotrieve]
31.
Munzenmaier, D. H.,
and Harder, D. R.
(2000)
Am. J. Physiol.
278,
H1163-H1167
32.
Cheng, T.,
Cao, W.,
Wen, R.,
Steinberg, R. H.,
and LaVail, M. M.
(1998)
Invest. Ophthalmol. Vis. Sci.
39,
581-591 33.
Ben-Av, P.,
Crofford, L. J.,
Wilder, R. L.,
and Hla, T.
(1995)
FEBS Lett.
372,
83-87[CrossRef][Medline]
[Order article via Infotrieve]
34.
Harada, S.,
Nagy, J. A.,
Sullivan, K. A.,
Thomas, K. A.,
Endo, N.,
Rodan, G. A.,
and Rodan, S. B.
(1994)
J. Clin. Invest.
93,
2490-2496[Medline]
[Order article via Infotrieve]
35.
Camp, R. D. R.,
Cunningham, F. M.,
Fincham, N. J.,
Greaves, M. W.,
Black, A. K.,
Mallet, A. I.,
and Woollard, P. M.
(1988)
Br. J. Pharmacol.
94,
1043-1050[Medline]
[Order article via Infotrieve]
36.
Folkman, J.,
and Brem, H.
(1992)
in
Inflammation: Basic Principles and Clinical Correlation
(Gallin, J. I.
, Goldstein, I. M.
, and Snyderman, A., eds)
, pp. 821-839, Raven Press, New York
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
F. Seta, L. Bellner, R. Rezzani, R. F. Regan, M. W. Dunn, N. G. Abraham, K. Gronert, and M. Laniado-Schwartzman Heme Oxygenase-2 Is a Critical Determinant for Execution of an Acute Inflammatory and Reparative Response Am. J. Pathol., November 1, 2006; 169(5): 1612 - 1623. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dronadula, F. Rizvi, E. Blaskova, Q. Li, and G. N. Rao Involvement of cAMP-response element binding protein-1 in arachidonic acid-induced vascular smooth muscle cell motility J. Lipid Res., April 1, 2006; 47(4): 767 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhang, H. Cao, and G. N. Rao Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis J. Biol. Chem., January 13, 2006; 281(2): 905 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mezentsev, V. Mastyugin, F. Seta, S. Ashkar, R. Kemp, D. S. Reddy, J. R. Falck, M. W. Dunn, and M. Laniado-Schwartzman Transfection of Cytochrome P4504B1 into the Cornea Increases Angiogenic Activity of the Limbal Vessels J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 42 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhang, H. Cao, and G. N. Rao 15(S)-Hydroxyeicosatetraenoic Acid Induces Angiogenesis via Activation of PI3K-Akt-mTOR-S6K1 Signaling Cancer Res., August 15, 2005; 65(16): 7283 - 7291. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dronadula, Z. Liu, C. Wang, H. Cao, and G. N. Rao STAT-3-dependent Cytosolic Phospholipase A2 Expression Is Required for Thrombin-induced Vascular Smooth Muscle Cell Motility J. Biol. Chem., January 28, 2005; 280(4): 3112 - 3120. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Neeli, Z. Liu, N. Dronadula, Z. A. Ma, and G. N. Rao An Essential Role of the Jak-2/STAT-3/Cytosolic Phospholipase A2 Axis in Platelet-derived Growth Factor BB-induced Vascular Smooth Muscle Cell Motility J. Biol. Chem., October 29, 2004; 279(44): 46122 - 46128. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ma, P. Ottino, H. E. P. Bazan, and N. G. Bazan Platelet-Activating Factor (PAF) Induces Corneal Neovascularization and Upregulates VEGF Expression in Endothelial Cells Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2915 - 2921. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jiang, A. Mezentsev, R. Kemp, K. Byun, J. R. Falck, J. M. Miano, A. Nasjletti, N. G. Abraham, and M. Laniado-Schwartzman Smooth Muscle--Specific Expression of CYP4A1 Induces Endothelial Sprouting in Renal Arterial Microvessels Circ. Res., February 6, 2004; 94(2): 167 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Yellaturu and G. N. Rao Cytosolic Phospholipase A2 Is an Effector of Jak/STAT Signaling and Is Involved in Platelet-derived Growth Factor BB-induced Growth in Vascular Smooth Muscle Cells J. Biol. Chem., March 7, 2003; 278(11): 9986 - 9992. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Z. Zeng, C. R. Yellaturu, I. Neeli, and G. N. Rao 5(S)-Hydroxyeicosatetraenoic Acid Stimulates DNA Synthesis in Human Microvascular Endothelial Cells via Activation of Jak/STAT and Phosphatidylinositol 3-Kinase/Akt Signaling, Leading to Induction of Expression of Basic Fibroblast Growth Factor 2 J. Biol. Chem., October 18, 2002; 277(43): 41213 - 41219. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||